Patients with familial hypercholesterolemia (FH) have markedly elevated plasma cholesterol levels and experience the consequences of accelerated coronary artery disease. Gene therapy for FH could be used to decrease the morbidity and mortality in these patients. Although intravenous gene therapy systems have the potential for treating various human diseases, the efficiency of gene transfer and expression remains insufficient for therapeutic purposes. 1 Among the current recombinant viral vectors, only adenoviral vectors produce the levels of gene expression required for a therapeutic response. For example, adenoviral vector transfer of the LDLR gene temporarily normalized cholesterol levels in mouse 2 and rabbit models of FH, 3, 4 while retroviral vector transfer was unsuccessful at normalizing cholesterol levels in rabbits 5 and humans. 6 However, adenoviral vectors have the potential to cause a fatal inflammatory immune response in the recipient. 7, 8 Cationic liposome DNA complex (CLDC) intravenous gene delivery has been shown to direct gene expression to vascular endothelial cells, monocytes, and macrophages. 9 CLDC gene delivery avoids immune system reactions associated with viral vectors, yet the low efficiency of gene delivery using CLDC has limited the use of nonviral vectors for gene therapy. 10 Ligandfacilitated transfer of CLDC has been shown to increase markedly in vitro gene delivery efficiency, 11, 12 but has not increased in vivo efficiency to the magnitude of adenoviral vectors 10 and has remained unsuccessful in applications to systemic gene therapy. Introduction of ligands such as transferrin and asialofetuin into a CLDC has been reported to generate in vivo expression of reporter plasmids, [13] [14] [15] [16] [17] while others report low transfer efficiency. 10 In the present study, a combination of CLDCtransferrin enhanced intravenous delivery of the LDLR gene in circulating leukocytes and reduced plasma LDL cholesterol levels in WHHL.
Pilot experiments in rats evaluated whether the use of CLDC-transferrin enhances the expression of reporter plasmid cDNA relative to CLDC. Male Sprague-Dawley (SD) rats weighing 300-350 g were infused intravenously with 10, 20, or 50 mg of pSV-b-galactosidase, pGL3-Control (Promega, Madison, WI, USA), or pAd CMV rLDLR as CLDC or CLDC-transferrin. Expression of pSV-b-galactosidase was examined histochemically. After 48 and 72 h, rats were anesthetized and lungs, heart, liver, and kidneys were excised and prepared for either LDLR mRNA PCR or histochemistry. Organ sections were incubated in X-gal staining solution and fixed tissues were examined by light microscopy for Xgal staining. Expression of pGL3-Control was detected by measuring firefly luciferase activity of tissue extracts as described. 18 Expression levels of the reporter plasmids in each organ were very low despite the use of CLDCtransferrin, whereas rabbit LDLR mRNA levels in the circulating leukocytes of rats receiving pAdCMV rLDLR as CLDC-transferrin were markedly higher than those receiving pAdCMV rLDLR as CLDC or control vector. An intravenous injection of relatively low doses of CLDC-transferrin could be expressed in circulating leukocytes.
WHHL receiving 100 mg pAdCMV rLDLR as CLDCtransferrin demonstrated a significant temporary decrease in plasma LDL cholesterol (Figure 1b) . LDL cholesterol levels decreased significantly after 4 days, reached a nadir of 75.473.6% at day 11, and returned to baseline 21 days after infusion. With the use of 50 mg pAdCMV rLDLR compared to 100 mg, the magnitude and duration of the decrease were diminished, but were still significant (Figure 1a) . Infusion of CLDC-transferrin dose dependently (50-100 mg) decreased plasma total cholesterol levels (Figure 1d In circulating leukocytes, LDLR mRNA was markedly increased to 380777% of baseline endogenous levels 4 . LDL (left panels) and total (right panels) cholesterol levels are expressed as per cent mean7SEM relative to the mean of all preinfusion values which was set to 100%. CLDC-transferrin was prepared as described. [18] [19] [20] Briefly, 300 ml of liposome was added to 200 ml HEPES-buffered saline (HBS, 20 mM HEPES, pH 7.4, and 100 mM NaCl) containing 1.6 mg human holo-transferrin, incubated for 20 min at room temperature, then mixed with 500 ml HBS containing either pAd CMV rLDLR or control vector and incubated for 15 min. pAdCMVrLDLR plasmid, constructed by substituting the rabbit LDLR for the LacZ expressing cassette in pAdCMVlacZ, 4 was the kind gift of James T Wilson (Institute for Human Gene Therapy, University of Pennsylvania, PA, USA). For each gene transfer experiment, six age-and sex-matched rabbits were used. Blood sampling and measurements of plasma cholesterols were performed twice weekly, and CLDC infusions were done after an initial observation period of 2 weeks comprising four baseline measurements. Measurement of plasma cholesterol and HPLC analyses were continued for 9 weeks after treatment. Plasma total, LDL, and HDL cholesterol levels were measured using L-type Wako Cholesterol (Wako Pure Chemical, Osaka, Japan), Cholestest LDL (Daiichi Pure Chemical, Tokyo, Japan), and HDL-C Direct Wako (Wako Pure Chemical). Mean preinfusion plasma LDL cholesterol levels were (a) 403721 and 410728 mg/dl, (b) 381722 and 402719 mg/dl, (c) 392726 and 360731 mg/dl, for open circles and closed circles, respectively. Mean preinfusion plasma total cholesterol levels were (d) 440723 and 454723 mg/dl, (e) 413734 and 440726 mg/dl, (f) 492724 and 492725 mg/dl, respectively. Experiments were repeated with comparable results and representative experiments are shown. *Po0.05 and **Po0.01 versus pre-infusion levels.
Receptor-operated transfer of LDL receptor gene M Shichiri et al days postinfusion (Figure 3 ). LDLR gene transcripts in the lung, heart, liver, and kidney were not increased following infusion. CLDC-transferrin efficiently expressed the LDLR gene in circulating leukocytes, yet this effect was transient as in previous animal models employing adenoviral vectors.
To examine if CLDC-transferrin could induce innate immune response in WHHL, plasma interleukin-6, plasma tumor necrosis factor-a, serum aspartate aminotransferase, serum alanine aminotransferase, serum alkaline phosphatase, and a white blood cell count were determined before and 1, 3, and 7 days postinfusion. None of these showed any significant increase after CLDC-transferrin. Six rabbits received second infusion of 50 mg pAdCMV rLDLR a week after initial CLDCtransferrin, again resulting in a significant therapeutic effect ( Figure 4) . These results suggest lack of a neutralizing immune reaction following CLDC-transferrin.
Ligand-facilitated gene transfer has been shown to enhance markedly transfection efficiency in vitro, yet successful in vivo application has not been forthcoming. Efficiency appears to be determined by several factors, such as the liposome design, 16 liposome to DNA ratio, 11 amount of DNA in the complex, 11 and the preparation of the CLDC. 9, 16 The transferrin-facilitated transfer of a CLDC was designed to generate high transfection efficiency in several mammalian cell lines. [18] [19] [20] The effect of intravenous delivery of a rabbit LDLR-expressing plasmid was examined as a model of intravenous gene therapy for FH. Our results demonstrate that use of transferrin enabled CLDC to be transfected and (c) Figure 2 HPLC profiles of plasma LDL and HDL. Plasma samples from WHHL receiving intravenous CLDC with or without transferrin were fractionated by HPLC and the cholesterol content of each fraction was measured. Representative profiles of rabbits at day À3, 11, and 18 with (a) 100 mg pAd CMV rLDLR as CLDC-transferrin, (b) 100 mg control empty vector as CLDC-transferrin, or (c) 100 mg pAd CMV rLDLR as CDLC are shown. HPLC was done on a TOSOH system (Tosoh, Tokyo, Japan) utilizing a high-speed chemical derivatization chromatograph. Each plasma lipoprotein was fractionated on two gel permeation columns (TSK Gel Lipopropak 300 Â 7.5 mm) with an eluent (TSK LP-1) flow rate of 0.3 ml/min. The cholesterol of each lipoprotein was selectively detected by monitoring the postcolumn effluent absorption at 550 nm following an enzymatic reaction at 451C in an on-line system, as described. 25 Receptor-operated transfer of LDL receptor gene M Shichiri et al expressed into circulating leukocytes, resulting in a significant reduction of plasma total and LDL cholesterol levels, demonstrating the feasibility of gene therapy for FH. However, despite the high-efficiency gene transfer, the genetic reconstitution and metabolic correction in WHHL were incomplete and transient as in previous adenoviral vector gene therapy. These may be caused by a rare integration of the plasmid DNA into the host genome and/or the short lifespan of mature leukocytes expressing CLDC-derived cDNA, considering the lack of immunological response to CLDC-transferrin. LDLR cDNA driven by cytomegalovirus promoter may also be subject to inactivation by methylation or other mechanisms.
Despite the limitations, this study illustrates the principle that hyperlipidemia can be ameliorated by a single intravenous injection of CLDC-transferrin containing a therapeutic gene. Inefficient expression in major organ tissues can be explained by the rapid and efficient clearance of CLDC-transferrin by circulating leukocytes before reaching the organs. Although the liver is the central organ for receptor-mediated clearance of LDL, circulating leukocytes also abundantly express LDLR which internalizes and degrades LDL molecules, contributing a large mass to the body. [21] [22] [23] [24] Thus, peripheral leukocytes could also serve as the target for adjunct gene therapy for familial hypercholesterolemia. Our results have also implications for applying this technology to other human diseases, especially those in which deficiency of a single gene can be replaced by transfer of an exogenous gene into circulating cells. Figure 3 Quantification of LDLR mRNA in circulating leukocytes before and after treatment. Expression of the LDLR because of CLDC-transferrin delivery was determined by quantifying LDLR mRNA before and after intravenous injection of pAd CMV rLDLR or control vector using a LightCyclert (Roche Molecular Biochemicals, Mannheim, Germany) PCR protocol, essentially as described, 18, [26] [27] [28] in which fluorescence emission caused by binding of SYBR Green I dye to amplified products is detected and measured. PCR primers were designed to detect both endogenous and transfected LDLR. Transcripts derived from the exogenous cDNA are expressed as a percent increase over endogenous LDLR mRNA (designated 100%). Total RNA from lung, heart, liver, kidney, and leukocytes was extracted using RNA zol Bt (TEL-TEST Inc., TX, USA) and QIAamp RNA Blood Mini Kits (Qiagen, KK, Tokyo, Japan), respectively. cDNA was synthesized with a First Strand cDNA synthesis kit (Amersham Pharmacia Biotech Inc, NJ, USA). TaqStartt antibody (CLONTECH, Palo Alto, CA, USA) was used to prevent generation of nonspecific amplification products. Quantification was performed using two sets of primers (forward primer-1 5 0 -GGACGTCTACTCCCTGGTGA-3 0 , reverse primer-1 5 0 -TGGAGTCCACCCAGTAGAGG-3 0 ; forward primer-2 5 0 -GATCCACGGCCACATCTACT-3 0 , reverse primer-2 5 0 -CCTCAAA-GATGGCCAGAGAG-3 0 ), both amplifying coding exons unrelated to the genetic mutations of WHHL, with comparable results. Fluorescence data were quantitatively analyzed using serial dilutions of the control sample to produce a standard curve, allowing relative quantification of templates. For verification of the melting curve results, PCR reactions were examined by electrophoresis on a 1.5% agarose gel. Data represent the mean7SEM of six determinations of the percentage of mRNA copies relative to control empty vector. *Po0.01, **Po0.005 versus control. 
